An New Therapeutic Approach
How It Works
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor. Reboxetine has an extensive safety record in Europe and in over 40 countries where it is approved for the treatment of Depression. AXS-12 in narcolepsy is supported by positive pre-clinical and preliminary clinical results where it significantly reduced narcoleptic episodes in hypocretin (orexin)-deficient mice as well as improving daytime sleepiness with reduced cataplexy in patients with narcolepsy in an open-label pilot trial.
Clinical and Regulatory
AXS-12 is currently being developed for the treatment of narcolepsy. We have received both orphan and breakthrough therapy designation from the FDA for AXS-12. A phase 3 trial is planned.